ArticleFrontiers in oncology2020

Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer.

Brad Rybinski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.